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Background: Cardiovascular disease accounts for the majority of morbidity and mortality in 
renal transplant patients. This relates to a number of modifiable and nonmodifiable risk factors, 
including new onset diabetes after transplantation (NODAT). We examined the prevalence of 
these risk factors in a cohort of 126 renal transplant patients.
Methods: A retrospective cross-sectional study of 94 nondiabetic post-transplant (ND) patients 
(mean age 45.7 ± 13.5 years) and 32 NODAT patients (55.2 ± 9.6 years) was performed. Univari-
ate linear regression analysis was used to identify potential factors that affected cardiovascular 
events. Multivariable analysis was performed on those factors found to achieve a P value of 
less than 0.20 after univariate analysis to test for significance in relation to cardiovascular risk 
as the primary factor.
Results: Mean serum creatinine levels were 131.1 ± 4.3 µmol/L and 135.2 ± 4.9 µmol/L at 
96.9 ± 8.7 and 79.4 ± 14.1 months post-transplantation, respectively. Systolic pressure and pulse 
pressure were significantly higher in NODAT patients (P = 0.016 and P , 0.005). Adequate target 
blood pressures were obtained in 80% of patients. Low-density lipoprotein and high-density 
lipoprotein cholesterol were reduced in NODAT (P = 0.04 and P = 0.005). Homocysteine was 
similarly elevated in both groups (17.5 and 15.6 µmol/L, respectively). Coronary events and/
or coronary disease were present in 19.1% of ND and 37.5% of NODAT patients (P , 0.05). 
Cardiac deaths were three-fold more   common (25% versus 7.4%) in patients with NODAT. 
Univariate analysis revealed diabetes and age, and subsequent multivariable analysis revealed 
age only, as being significantly associated with cardiovascular outcomes.
Conclusions: Cardiac events are more common in patients with NODAT. Age is an important 
determinant of cardiovascular risk.
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Introduction
Compared with the general population, cardiovascular disease in renal transplant 
recipients accounts for the majority of their morbidity and mortality.1–3 Although 
cardiovascular mortality has improved in transplant recipients compared with dialysis 
patients, it remains a significant problem.4 The estimated incidence of ischemic heart 
disease in renal transplant recipients is approximately 15% in comparison with 4% in 
the general population.5 This relates to a number of traditional potentially modifiable 
risk factors, including lipid abnormalities, diabetes mellitus, hypertension, tobacco 
intake, and elevated pulse pressure, and nonmodifiable risk factors, including gender, 
age, and family history. Newer potential risk factors identified include fibrinogen levels 
and elevated homocysteine levels.6 Other potential risk factors related   specifically to International Journal of Nephrology and Renovascular Disease 2010:3 submit your manuscript | www.dovepress.com
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transplantation include immunosuppressive therapy, acute 
rejection episodes, cytomegalovirus infection, anemia, 
proteinuria, and new onset diabetes after transplantation 
(NODAT). More recently emerging evidence has suggested 
that fibroblast growth factor-23, vitamin D, and disorders of 
mineral metabolism (including hyperparathyroidism, and cal-
cium and phosphate levels) in relation to vascular calcifica-
tion and arterial stiffness may be important in cardiovascular 
disease progression and cardiac events. Mechanistic factors 
involving inflammation, oxidative stress, and endothelial 
injury may all interact in this complex cardiovascular milieu 
to create an adverse risk in this population.7–9
Approximately 20% of recent transplant recipients are 
diabetic at the time of transplantation. Post-transplant diabe-
tes is relatively common and is on the increase, occurring in 
up to 2%–46% of patients, especially with the use of newer 
immunosuppressive therapies.10 It represents an additional 
major risk factor for subsequent cardiac disease. Indeed, 
fasting blood glucose values in the upper normal range are 
associated with an increased risk for death from cardio-
vascular causes.11 Impaired nonoxidative glucose disposal 
explains the insulin resistance observed in NODAT similar 
to that observed in patients with type 2 diabetes mellitus in 
the general population.12 However, the extent of the problem 
in patients with long-standing transplants remains obscure.
Experience from our review of diabetic patients receiving a 
renal allograft indicates a high mortality from cardiac and infec-
tious causes (unpublished data, Bhandari et al). At this center, 
historically almost 48% of diabetics diagnosed pretransplanta-
tion have died within five years of transplantation from cardiac 
causes, while a further 29% have died from infective causes. 
The aim of the present study was to examine cardiac risk fac-
tors (lipids, homocysteine,   smoking, glycemia, duration of 
transplantation, serum albumin, blood pressure, uric acid, pulse 
pressure, age and gender,   immunosuppressive regime, use of 
statins, use of angiotensin-converting enzyme inhibitors, and 
etiology of primary renal disease) in a cohort of Australian renal 
transplant recipients with and without NODAT and to compare 
the incidence of cardiac events after transplantation.
Patient and methods
We retrospectively performed a cross-sectional analysis using 
the departmental renal data system in a single regional renal 
transplant center of patients receiving renal allografts (deceased 
donor, live related/unrelated) from 1978 to 2000. All patients 
were aged less than 60 years at the time of transplantation. 
Patients with diabetes prior to renal allograft   transplantation 
were excluded from the study. Patients with a documented 
or known prior cardiovascular event were not included in the 
study. Patients were classified into two groups, ie, nondiabetics 
(ND) and those with NODAT. Diabetes prior to transplantation 
was defined according to standard   criteria for diagnosis, and 
any patient with a known history of documented diabetes at 
any time (continuous or for a short period), whether requir-
ing dietary glucose restriction or oral hypoglycemic agents or 
insulin, was excluded from the study population. NODAT was 
defined as no pretransplant diabetes and   development of dia-
betes post-transplantation. A fasting glucose of .6 mmol/L, 
a random glucose of .11.1 mmol/L, or the use of diet or 
oral hypoglycemic agents and/or insulin to normalize blood 
  glucose was considered diagnostic for diabetes. ND patients 
had neither any pretransplant diabetes nor any new onset dia-
betes mellitus after transplantation. A fasting/random glucose 
of ,5.5 mmol/L was considered to be ND. Patients were not 
screened for impaired glucose tolerance. We investigated a 
total of 126 patients, comprising 94 ND (56 male and 38 
female) and 32 NODAT patients (16 male and 16 female). Car-
diovascular events were identified from case records. Criteria 
for diagnosis of a cardiovascular event were acute myocardial 
infarction, hospitalization for acute coronary syndrome, hos-
pitalization for symptomatic angina, percutaneous coronary 
intervention, or coronary bypass surgery (after a diagnosis of 
NODAT or in the ND group). Stress testing and requirement 
for cardiac angiography was considered at the discretion of 
the caring physician in conjunction with a cardiology opinion. 
No predefined protocol was in place at the time of the study 
for cardiovascular surveillance. A history of hypertension 
and smoking was noted. A history or evidence of carotid 
artery disease or peripheral vascular disease was recorded 
for analysis. Three blood pressure recordings from separate 
clinic visits were recorded and averaged. Hypertension in 
this study was defined as a systolic pressure .140 mmHg 
and/or a diastolic pressure .90 mmHg according to the criteria 
of the Seventh Report of the Joint National Committee on 
  Prevention, Detection, and evaluation of High Blood Pressure. 
Left ventricular hypertrophy was diagnosed in accordance with 
Sokolow–Lyon criteria.
Fasting plasma homocysteine levels were determined by 
high-performance liquid chromatography with fluorescence 
detection. Postload homocysteine was not performed because 
this has been shown to provide little more information in 
addition to measurement of homocysteine alone.13 Additional 
blood samples were analysed for plasma glucose, glycosy-
lated hemoglobin (HbA1c), total cholesterol, high-density International Journal of Nephrology and Renovascular Disease 2010:3 submit your manuscript | www.dovepress.com
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lipoprotein (HDL) cholesterol, triglycerides, uric acid, and 
serum albumin. Low-density lipoprotein (LDL) cholesterol 
was estimated with the Friedewald equation. HbA1c was 
determined in whole blood (ethylenediamine tetra-acetic acid 
tube). Triglycerides were measured by standard enzymatic 
calorimetric test.
statistical analysis
All statistical analysis was carried out using SPSS for 
  Windows (version 14; SPSS Inc., Chicago, IL). All 
continuous variables were expressed as means and standard 
deviation. Skewed data were logarithmically transformed 
to meet the assumptions of the statistical analysis. The 
Mann–Whitney test was used for skewed distribution data. 
Two-sided unpaired t-tests, or one way analysis of variance, 
and Tukey’s test were used to compare means between the 
two groups (ND and NODAT, see Table 1) to seek differ-
ences. Linear regression analysis was performed to evaluate 
univariate and multivariable clinical and biochemical pre-
dictors of cardiovascular events in relation to conventional 
cardiovascular risk factors. The dependent variable for which 
each potential risk factor (characteristic) was examined was 
cardiovascular events. Multivariable analysis was performed 
on those “putative” cardiovascular risk factors found to 
reach a P value of less than 0.20 after univariate analysis 
to test for significance in relation to cardiovascular risk as 
Table 1 summary of analysis of patients
Characteristic NODAT 
(mean ± SD)
ND 
(mean ± SD)
P values initial 
analysis
P values 
multivariable 
analysis
Patient characteristics  
  Age
 
55.2 ± 9.6
 
45.69 ± 13.54
 
0.001
 
0.001
  sex (M:F) 16:16 56:38 0.3 0.685
  systolic BP (mmhg) 134.22 ± 15.7 126.32 ± 14.6 0.016 0.308
  Diastolic BP (mmhg) 82.65 ± 8.9 81.48 ± 8.48 0.47 0.529
  Pulse pressure 51.56 ± 12.98 44.89 ± 10.90 ,0.005 0.12
  Left ventricular hypertrophy 7 (23%) 22 (22%) Ns
  carotid artery disease 0 7 (8%) Ns
  Peripheral vascular disease 2 (7.8%) 5 (5.3%) Ns
smoking  
  current
 
4 (12.5%)
 
16 (17%)
 
Ns
  ex 4 (12.5%) 8 (8.5%) Ns
  Nonsmoker 17 (53.1%) 56 (59.6%) Ns
  Unknown 7 (21.9%) 14 (14.9%) Ns
Biochemistry  
  hDL cholesterol (mmol/L)
 
1.32 ± 0.42
 
1.62 ± 0.53
 
0.0048
 
0.660
  LDL cholesterol (mmol/L) 2.30 ± 0.74 2.67 ± 0.77 0.039 0.535
  hDL/LDL cholesterol 0.68 ± 0.39 0.68 ± 0.34 0.99 0.55
  Total cholesterol (mmol/L) 5.1 ± 1.03 4.73 ± 0.94 0.074 0.565
  Triglycerides (mmol/L) 1.76 ± 0.82 2.94 ± 3.7 ,0.001 0.454
  homocysteine (µmol/L) 15.57 ± 4.26 17.53 ± 9.09 0.26 0.524
  Albumin (g/L) 39.3 ± 2.9 38.96 ± 2.84 0.14 0.285
  hbA1c (%) 7.08 ± 1.33 5.56 ± 0.49 ,0.001 0.313
  Uric acid (mmol/L) 0.50 ±  0.11 0.47 ± 0.13 0.28 0.523
(n) (%) (n) (%)
Immunosuppression  
and number of agents 
No differences in type of immunosuppression with cardiac events as the  
dependent factor
Ns
statin use (n) 22 (69) 46 (49)
AceI 11 (34) 45 (48)
Duration after transplant 
(months)
79.4 ± 14.1 96.9 ± 8.7 0.001 Ns
Notes: P values in first column relate to analysis of variance for patients with and without new-onset diabetes after transplantation. The second column relates to 
multivariable analysis of significant variables on univariate analysis using linear regression with cardiovascular events as the dependent variable for which only diabetes and 
age had initial P values less than 0.05. 
Abbreviations: AceI, angiotensin-converting enzyme inhibitors; BP, blood pressure; hbA1c, glycosylated hemoglobin; hDL, high-density lipoprotein; LDL, low-density 
lipoprotein; ND, nondiabetic post-transplantation; NODAT, new onset diabetes post-transplantation; M, male; F, female.International Journal of Nephrology and Renovascular Disease 2010:3 submit your manuscript | www.dovepress.com
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the dependent factor. This was carried out by a stepwise 
regression by sequentially removing variables one at a time 
until only significant variables remained. A value of P , 0.05 
was considered statistically significant.
Results
Ninety-four ND patients (56 men and 38 women) of mean 
age 45.7 ± 13.5 years and 32 NODAT patients (16 men 
and 16 women) of mean age 55.2 ± 9.6 years were   studied 
(11 insulin-requiring and 21 requiring only an oral 
hypoglycemic agent). Causes of renal failure included 
  autosomal dominant polycystic kidney disease (n = 14), 
reflux   nephropathy (n = 13), Alport’s kidney disease (n = 1), 
  mesangiocapillary glomerulonephritis (n = 8), rapidly progres-
sive glomerulonephritis (n = 6), chronic   glomerulonephritis 
(11), undetermined etiology (n = 14), analgesic nephropathy 
(n = 8), IgA nephropathy (n = 22), focal segmental glom-
erulosclerosis (n = 8), hypertension (n = 4), systemic lupus 
erythematosus (n = 3), obstructive uropathy (n = 3), dysplastic 
kidneys (n = 3), membranous glomerulonephritis (n = 3), 
hemolytic uremic syndrome (n = 1), renovascular disease 
(n = 1), postinfectious glomerulonephritis (n = 1), vasculitis 
(n = 1) and cystinosis (n = 1). Immunosuppressive regimes 
used in these patients were as detailed in Table 2.
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Figure 1 glycemic control as measured by hBA1c levels and fasting glucose in 
transplant patients with (NODAT) and without (ND) new onset diabetes after 
transplantation. 
Table  2  summary  of  immunosuppression  used  in  transplant 
patients and etiology of primary renal disease
Immunosuppression n (%) n (%)
  corticosteroids 30 (94) 90 (96)
  cyclosporine 19 (59) 51 (54)
  Tacrolimus 3 (9.3) 6 (6.3)
  Azathioprine 17 (53) 54 (57.4)
  Mycophenolate 9 (28) 23 (24.5) 
  sirolimus 4 (12.5) 7 (7.4) 
Agents (n) 
 0 0 (0) 1 (1)
 1 1 (3.1) 6 (6.4)
 2 12 (37.5) 35 (37.2)
 3 19 (59.4) 52 (55.3)
cause of end-stage renal failure
  IgA 6 (20) 16 (17.8) 
  Mesangio capillary glomerulonephritis 2 (6.7) 6 (6.7)
  Polycystic kidney disease 5 (16.7) 9 (10)
  glomerulonephritis/chronic 5 (16.7) 6 (6.6)
  Analgesics 4 (13.3) 4 (4.4)
  Reflux/obstruction 4 (13.3) 12 (13.3)
  hypertension/nephrosclerosis 3 (10) 1 (1.1)
  Vasculitis/systemic lupus erythematosus 2 (6.7) 8 (8.9)
  Focal segmental glomerulosclerosis 1 (3.3) 7 (7.7)
  Others  8 (8.9)
  Unknown 14 (15.6)
  Dysplastic 3 (3.3)
NODAT patients were significantly older (P = 0.001), but 
there was no difference in gender and history of smoking. 
NODAT was more common in patients with polycystic   kidney 
disease (16.7% versus 10%) and in patients with   analgesic 
nephropathy (13.3% versus 4.4%) as a cause of renal disease 
(Table 2). Most patients received double or triple immuno-
suppressive therapy (97% and 93% for NODAT and ND, 
respectively). Both glucose and HBA1c concentrations were 
significantly elevated in NODAT (P , 0.001, Figure 1) but 
the levels in this group were adequately controlled.
Univariate analysis revealed that both age (P , 0.001) 
and diabetes (P , 0.05) were significant risk factors for 
cardiovascular events as the dependent variable. However, 
after multivariable analysis, only age remained as the pre-
dominant significant risk factor (P , 0.001), while diabetes 
was no longer significant (P = 0.47).
Renal function
Mean serum creatinine concentrations were 131.1 ± 4.3 µmol/L 
and 135.2 ± 4.9 µmol/L (P = NS), respectively, between 
ND and NODAT patients at mean times of 96.9 ± 8.7 and 
79.4 ± 14.1 months post-transplantation.
Lipids
HMG-CoA reductase inhibitor (statin) therapy was used in 
54% of patients. LDL cholesterol levels were lower in the 
NODAT group (2.3 ± 0.74 mmol/L versus 2.7 ± 0.77 mmol/L, 
respectively, P = 0.039). Forty-six percent of patients had total 
cholesterol levels .5 mmol/L (12 NODAT and 46 ND), and 
34% had low-density lipoprotein (LDL) cholesterol levels 
greater than 3 mmol/L (35 ND and 8 NODAT) despite lipid-
lowering therapy. High-density lipoprotein (HDL) cholesterol International Journal of Nephrology and Renovascular Disease 2010:3 submit your manuscript | www.dovepress.com
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concentrations were lower in NODAT patients. The median 
total cholesterol:HDL ratio was 3.3 (range 1.53–6.8), with 
11% of patients having ratios .5. Triglyceride levels were 
markedly elevated in patients with NODAT (Figure 2).
homocysteine
Homocysteine levels were similarly elevated in both groups 
(17.5 µmol/L and 15.6 µmol/L, respectively, Figure 3), 
and 78% had a level greater than 12 µmol/L. There was a 
positive correlation of homocysteine with serum creatinine 
(r = 0.3), age (r = 0.32), and serum albumin (r = 0.4). This 
correlation was more pronounced in patients with NODAT. 
Previously it has been noted that transplant patients on 
cyclosporine tend to have higher homocysteine levels.14 
However, we found no such trend in this select cohort of 
transplant patients.
cardiovascular disease
A history of or current hypertension requiring ther-
apy was present in 68% of ND and 87% of NODAT 
patients. Systolic blood pressure and pulse pressure were 
significantly higher in NODAT (P = 0.016 and P , 0.005, 
respectively, Figure 4). ACE inhibitors and/or angiotensin 
II receptor antagonists were used in 40% of NODAT and 
48% of ND patients. Eleven female and five male patients 
had a systolic blood pressure greater than 140 mmHg (all on 
treatment), four female and six male patients had a diastolic 
blood pressure greater than 90 mmHg (all but one on therapy), 
and three each had both elevated systolic and diastolic blood 
  pressures. Adequate target blood pressures (,140/90 mmHg) 
were obtained in 80% of patients. Twenty-nine patients (23% 
versus 22% for ND and NODAT, respectively) had electro-
cardiographic criteria for left ventricular hypertrophy, with 
no statistically significant difference found between groups. 
Albumin and uric acid levels were similar in both groups and 
not related to cardiac events.
In total, seven patients (8%) in the ND group had 
  documented evidence of carotid artery disease versus none 
in the NODAT group, but the data set was incomplete, and 
analysis revealed no significance association with cardiac 
events. Seven patients also had evidence of peripheral 
vascular disease, again with an incomplete data set, and no 
association was found with cardiovascular events.
Symptomatic cardiovascular events were present in 
19.1% (n = 18) of ND and 37.5% (n = 12) of NODAT 
patients (P , 0.05). For NODAT patients, there were six 
documented myocardial infarctions, for one of which surgery 
was subsequently required. Six patients had acute coronary 
syndrome or angina. Three patients with acute coronary syn-
drome or who had had a myocardial infarction required 
subsequent angiography and/or angioplasty. For ND patients, 
there were 14 myocardial infarctions, three of which had 
subsequent coronary artery bypass grafts. Four patients 
had acute coronary syndrome or angina. Seven patients in 
the ND group of 18 patients with cardiovascular events had 
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Figure 2 Lipid profiles in transplant patients with (NODAT) and without (ND) 
in the presence of new onset diabetes after transplantation.
Abbreviations: LDL, low-density lipoprotein; hDL, high-density lipoprotein; ND, 
nondiabetic; NODAT, new onset diabetes after transplantation.
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Figure 3 Mean fasting homocystine levels in patents with (NODAT) and without 
(ND) new onset diabetes after transplantation.
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Figure 4 Blood pressure control in transplant patients with (NODAT) and without 
(ND) new onset diabetes after transplantation.
Abbreviations: BP, blood pressure; ND, nondiabetics; NODAT, new onset diabetes 
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angiography and/or angioplasty. Using cardiovascular events 
as the dependent variable, analysis of variance factored age 
and diabetes as candidate variables and age as a potential 
adverse risk factor for cardiac event rates after multivariable 
analysis (Table 1). Over the entire follow-up period, there 
were 35 (27.8%) deaths, of which 18 (56.3%) occurred in the 
NODAT group and 16 (17%) in the ND group. In the NODAT 
group there were eight (25%) deaths reported as being cardiac 
in nature. The remaining deaths were due to sepsis (n = 7), 
unknown cause (n = 2), and carcinoma (n = 1). In the ND 
group, seven (7.4%) deaths were reported as cardiac and nine 
noncardiac (sepsis n = 3, carcinoma n = 2, unknown n = 3, 
and stroke n = 1).
Discussion
Cardiovascular risk factors were highly prevalent in this 
cohort of transplant patients. More than 90% of patients had 
recognized cardiovascular risk factors. Despite   reasonably 
good blood pressure and lipid control, the incidence of 
  cardiovascular events overall in this cohort of patients 
was 23%. Our objective was to determine whether the devel-
opment of NODAT might represent a mediator in the rela-
tionship of traditional cardiovascular risk factors, metabolic 
abnormalities, and cardiovascular disease.   Cardiovascular 
events were especially more prevalent in those patients 
with NODAT (37.5% versus 19.1%). Both age and male 
gender are important risk factors for cardiovascular disease 
in transplant patients.2 In considering what mechanisms 
may be responsible for the higher cardiovascular risk among 
individuals with NODAT, we observed that NODAT indi-
viduals were older than those with ND, but there was no 
gender difference. ND patients also had functioning grafts 
for a longer period of time (on average 16 months). However, 
although there was a strong association of NODAT with 
cardiac complications in the unadjusted analysis, the asso-
ciation was attenuated after statistical adjustment for demo-
graphic parameters and   confounding risk factors previously 
  associated with   cardiovascular disease (Table 1). Mortality 
was significantly higher in the NODAT group (56.3% versus 
17%) over the course of follow-up (mean 91 months), with 
cardiac deaths accounting for 12% of all deaths in this cohort 
of 126   transplant patients and occurring at least three-fold 
more often in patients with NODAT (25% versus 7.4%).
Blood pressure was adequately controlled, but both 
  systolic and pulse pressure were significantly higher in 
patients with NODAT. Good control of blood pressure 
  perhaps is an essential part of management to preserve 
renal function and reduce overall cardiovascular risk. 
  Hypertension was prevalent but similar in both groups.   
In total, 75%–90% of patients with functioning renal 
  transplants have   hypertension and 55% do not achieve target 
blood pressure.15,16 Our data indicate much better control, 
thus reducing cardiovascular risk and potentially improving 
long-term transplant outcomes.
Post-transplantation patients tend to have elevated total 
cholesterol, triglycerides, LDL, and normal or elevated 
HDL.10 Indeed, the prevalence of this pattern of biochemical 
changes occurs in up to 60% of patients, which may lead to 
increased future cardiovascular risk. This relates in part to 
immunosuppressive therapy, especially steroids, calcineurin 
inhibitors, and, more recently, rapamycin.17 Many random-
ized controlled trials in nontransplant patients have shown a 
reduction in cardiovascular risk via lowering of cholesterol 
concentrations.18,21 In transplant patients, currently only the 
ALERT (Assessment of Lescol in Renal Transplantation) 
study has shown a benefit of lipid-lowering therapy in this 
population.22,23 Although there was no reduction in primary 
endpoints, secondary endpoints showed a 35% reduction of 
cardiac death and nonfatal myocardial infarction. This finding 
was significant and similar to other nontransplant studies. 
Statins may also have other additional pleiotropic effects 
beyond lowering LDL cholesterol, including nitric oxide 
production in endothelium, an independent antihypertensive 
effect, an antithrombotic effect through reduced thromboxane 
production, and an anti-inflammatory effect.19 Several reports 
indicate that use of statins early during transplantation cor-
relates with improved renal allograft survival independent of 
cholesterol or triglyceride levels.24 LDL and HDL cholesterol 
levels were lower in NODAT patients, but the HDL:LDL 
ratio was higher overall in more patients with NODAT. 
HDL cholesterol is a strong independent predictor for the 
development of and death from ischemic heart disease.2,3 
In addition, raised triglycerides increase the risk of ischemic 
heart disease, but this measure remains difficult to evaluate 
in the clinical context.2 Our data suggest that although lipid 
levels were reasonable, the lower LDL and HDL levels in 
the NODAT group could also reflect a higher prevalence of 
metabolic syndrome (reflected by NODAT). Therefore, in 
addition to more aggressive management of dyslipidemia, 
diet and exercise may be beneficial for optimal cardiovascular 
risk reduction. Indeed, examination of insulin resistance and 
factors such as body mass index and waist circumference 
may have been useful adjuncts in global assessment of this 
cohort of patients.
Homocysteine is a sulfur-containing amino acid, the 
metabolism of which depends on vitamin B12 and folic acid. International Journal of Nephrology and Renovascular Disease 2010:3 submit your manuscript | www.dovepress.com
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Plasma levels of homocysteine are raised markedly in dialysis 
patients. Homocysteine levels continue to rise following renal 
or cardiac transplantation, independent of renal function.25,26 
This has been associated with adverse cardiovascular mor-
bidity and overall mortality.1 Elevated homocysteine levels 
and lipids are graded as independent risk factors for cardio-
vascular and generalized atherosclerotic disease comparable 
with smoking.13 A 5 µmol/L increment in fasting/nonfasting 
homocysteine levels is associated with a 25%–30% increase 
in coronary heart disease risk.27 In this study, homocysteine 
levels were high in the majority of patients (83%) and reduced 
with time post-transplantation, but remained significantly 
higher (approximately 5 µmol/L) than the normal range. 
Serum folate levels were normal in this cohort of patients. 
Hyperhomocysteinemia perhaps contributes to the overall 
increased cardiovascular risk in this transplant group, but is 
not influenced by the presence of diabetes.
NODAT is a complication of immunosuppression. Its 
incidence amounts to approximately 18%.28 Many risk factors 
have been proposed for the development for NODAT, includ-
ing a family history of diabetes mellitus, human leukocyte 
antigens (HLA) A28, A30, B8, B27, and BW42, African-
American and Hispanic ethnicity, tacrolimus use, and steroid 
dose.10,28,29 Risk factors with limited supporting evidence 
include pretransplant renal failure due to interstitial nephritis 
and polycystic kidney disease, deceased donor rather than 
haploidentical living graft,30 number of episodes of acute 
rejection, longer duration of dialysis prior to transplantation, 
interleukin-6 gene promoter polymorphism, hepatitis C virus 
infection, and higher body mass index.10
Steroids and calcineurin antagonists contribute to the 
increased prevalence of NODAT.31 The need to avoid NODAT 
has to be a consideration in the choice of immunosuppressive 
regime. However, modification to the immunosuppression 
regime needs to be weighed carefully against the risk of 
rejection.
The impact of NODAT on cardiovascular morbidity and 
mortality is somewhat obscure. Mortality was significantly 
higher in our NODAT group, but age was the most significant 
risk factor, with the ND patients being a decade younger. 
Therefore, the effects of good glycemic control are less clear. 
Pretransplant diabetes mellitus is an established and power-
ful predictor for death from ischemic heart disease in renal 
transplant recipients.3 Diabetic patients have a high incidence 
of asymptomatic cardiovascular disease.20 Therefore, in this 
population, given the high incidence of NODAT (25.4%), it 
might be pertinent to monitor these patients prospectively 
and perhaps offer aggressive risk factor management and 
elective angiography and/or angioplasty before significant 
vascular complications occur. Several authors have suggested 
performing an oral glucose tolerance test to detect impaired 
glucose tolerance and instituting cardiovascular risk reduc-
tion strategies even before a diagnosis of NODAT is made.32 
Prospective comparative data are needed to examine this 
phenomenon more closely. Perhaps good glycemic control 
may have beneficially contributed to the relatively good 
survival in our cohort.
Summary
This study presents some intriguing findings in patients 
with long-term functioning renal transplants. Older age 
represents the strongest risk factor for cardiovascular 
events. Although NODAT is a significant risk factor in 
univariate analysis, its effect is diluted in multivariable 
analysis, perhaps by the large age difference. However, 
we believe that vigilance in   detecting and tightly control-
ling or preventing NODAT may be important for limiting 
cardiovascular risk and eventual death with a functioning 
graft. Equally it may well be that diabetes per se does not 
lead to cardiac disease, but is a surrogate marker for it. 
Perhaps immunosuppressive therapy should be tailored 
to reducing this increasing problem and thereby avoiding 
cardiovascular events. Hence equally potent drugs are 
required without the adverse effects on the metabolic pro-
file. The strong association between age and cardiovascular 
risk in transplant patients may have implications with 
regards to addressing cardiovascular risk more aggres-
sively in older potential transplant recipients.
This study has several limitations. One acknowledges 
that this was a retrospective observational cross-sectional 
study in an Australian cohort of transplant recipients and 
that small numbers were used. However, it does highlight 
some interesting findings. Silent myocardial ischemia 
is common in this high-risk population, and we cannot 
exclude a   number of patients having occult coronary 
artery disease with few clinical symptoms. In relation 
to metabolic   syndrome, data on waist circumference and 
proteinuria may have been   helpful but were not available. 
Therefore,   prospective   studies are necessary to investigate 
any potential causal relationship between NODAT and car-
diovascular endpoints. Larger numbers would be necessary 
to remove possible type 2 errors occurring and to see if 
interventions to reduce risk factors lead to overt reduc-
tions in   cardiovascular risk. No examination of other risk 
factors, including anemia, was undertaken, and therefore 
represents another limitation to the study.International Journal of Nephrology and Renovascular Disease
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